

Tobias Welte

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7156145/publications.pdf>

Version: 2024-02-01

351
papers

23,908
citations

11646
70
h-index

10732
138
g-index

371
all docs

371
docs citations

371
times ranked

29248
citing authors

#	ARTICLE	IF	CITATIONS
1	Gender-specific differences in COPD symptoms and their impact for the diagnosis of cardiac comorbidities. <i>Clinical Research in Cardiology</i> , 2023, 112, 177-186.	3.3	9
2	Key summary of German national treatment guidance for hospitalized COVID-19 patients. <i>Infection</i> , 2022, 50, 93-106.	4.7	30
3	Criteria and definitions for the radiological and clinical diagnosis of bronchiectasis in adults for use in clinical trials: international consensus recommendations. <i>Lancet Respiratory Medicine</i> , 2022, 10, 298-306.	10.7	70
4	Clinical decision making is improved by BioFire Pneumonia Plus in suspected lower respiratory tract infection after lung transplantation: Results of the prospective DBATE study. <i>Transplant Infectious Disease</i> , 2022, 24, e13725.	1.7	7
5	Chest Infections After Lung Transplantation. <i>Chest</i> , 2022, 161, 937-948.	0.8	5
6	A longitudinal analysis of pneumococcal vaccine serotypes in pneumonia patients in Germany. <i>European Respiratory Journal</i> , 2022, 59, 2102432.	6.7	19
7	Altered fibrin clot structure and dysregulated fibrinolysis contribute to thrombosis risk in severe COVID-19. <i>Blood Advances</i> , 2022, 6, 1074-1087.	5.2	35
8	Improving vaccination rates in older adults and at-risk groups: focus on pertussis. <i>Aging Clinical and Experimental Research</i> , 2022, 34, 1-8.	2.9	10
9	Combining baloxavir marboxil with standard-of-care neuraminidase inhibitor in patients hospitalised with severe influenza (FLAGSTONE): a randomised, parallel-group, double-blind, placebo-controlled, superiority trial. <i>Lancet Infectious Diseases</i> , 2022, 22, 718-730.	9.1	30
10	Acute Phase Proteins as Early Predictors for Immunotherapy Response in Advanced NSCLC: An Explorative Study. <i>Frontiers in Oncology</i> , 2022, 12, 772076.	2.8	8
11	Time-Dependent Molecular Motifs of Pulmonary Fibrogenesis in COVID-19. <i>International Journal of Molecular Sciences</i> , 2022, 23, 1583.	4.1	16
12	Observational study of changes in utilization and outcomes in mechanical ventilation in COVID-19. <i>PLoS ONE</i> , 2022, 17, e0262315.	2.5	21
13	Reduced decline of lung diffusing capacity in COPD patients with diabetes and metformin treatment. <i>Scientific Reports</i> , 2022, 12, 1435.	3.3	8
14	Risk Assessment for Patients with Chronic Respiratory Conditions in the Context of the SARS-CoV-2 Pandemic Statement of the German Respiratory Society with the Support of the German Association of Chest Physicians. <i>Respiration</i> , 2022, 101, 307-320.	2.6	5
15	ECMO during the COVID-19 pandemic: moving from rescue therapy to more reasonable indications. <i>European Respiratory Journal</i> , 2022, 59, 2103262.	6.7	11
16	B Cells Are Not Involved in the Regulation of Adenoviral TGF- β or Bleomycin-Induced Lung Fibrosis in Mice. <i>Journal of Immunology</i> , 2022, 208, 1259-1271.	0.8	6
17	Transmembrane serine protease 2 is a prognostic factor for lung adenocarcinoma. <i>International Journal of Oncology</i> , 2022, 60, .	3.3	5
18	Comparative Analysis of Gene Expression in Fibroblastic Foci in Patients with Idiopathic Pulmonary Fibrosis and Pulmonary Sarcoidosis. <i>Cells</i> , 2022, 11, 664.	4.1	12

#	ARTICLE	IF	CITATIONS
19	Clinical and Microbiological Effects of an Antimicrobial Stewardship Program in Urology—A Single Center Before-After Study. <i>Antibiotics</i> , 2022, 11, 372.	3.7	5
20	Interstitial lung disease in infancy and early childhood: a clinicopathological primer. <i>European Respiratory Review</i> , 2022, 31, 210251.	7.1	10
21	Evaluation of the oral corticosteroid-sparing effect of tezepelumab in adults with oral corticosteroid-dependent asthma (SOURCE): a randomised, placebo-controlled, phase 3 study. <i>Lancet Respiratory Medicine</i> , 2022, 10, 650-660.	10.7	51
22	Organ manifestations of COVID-19: what have we learned so far (not only) from autopsies?. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2022, 481, 139-159.	2.8	28
23	PREFUL MRI Depicts Dual Bronchodilator Changes in COPD: A Retrospective Analysis of a Randomized Controlled Trial. <i>Radiology: Cardiothoracic Imaging</i> , 2022, 4, e210147.	2.5	11
24	Age- and gender-based comorbidity categories in general practitioner and pulmonology patients with COPD. <i>Npj Primary Care Respiratory Medicine</i> , 2022, 32, 17.	2.6	3
25	Clinical and biochemical endpoints and predictors of response to plasma exchange in septic shock: results from a randomized controlled trial. <i>Critical Care</i> , 2022, 26, 134.	5.8	21
26	A Morphomolecular Approach to Alveolar Capillary Dysplasia. <i>American Journal of Pathology</i> , 2022, 192, 1110-1121.	3.8	6
27	Vaccination and modern management of chronic obstructive pulmonary disease — a narrative review. <i>Expert Review of Respiratory Medicine</i> , 2022, 16, 605-614.	2.5	3
28	Update June 2022: management of hospitalised adults with coronavirus disease 2019 (COVID-19): a European Respiratory Society living guideline. <i>European Respiratory Journal</i> , 2022, 60, 2200803.	6.7	22
29	Role of matrix metalloprotease-2 and MMP-9 in experimental lung fibrosis in mice. <i>Respiratory Research</i> , 2022, 23, .	3.6	23
30	Effect of Therapeutic Plasma Exchange on Immunoglobulin Deficiency in Early and Severe Septic Shock. <i>Journal of Intensive Care Medicine</i> , 2021, 36, 1491-1497.	2.8	8
31	SARS-CoV-2—triggered Immune Reaction: For COVID-19, Nothing Is as Old as Yesterday's Knowledge. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2021, 203, 156-156.	5.6	4
32	Immunoglobulin deficiency as an indicator of disease severity in patients with COVID-19. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 2021, 320, L590-L599.	2.9	17
33	Role of the COX2-PGE ₂ axis in <i>S. pneumoniae</i> -induced exacerbation of experimental fibrosis. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 2021, 320, L377-L392.	2.9	8
34	Clinical Molecular Imaging of Pulmonary CXCR4 Expression to Predict Outcome of Pirfenidone Treatment in Idiopathic Pulmonary Fibrosis. <i>Chest</i> , 2021, 159, 1094-1106.	0.8	23
35	A Before-and-After Study of Evidence-Based Recommendations for On-Call Bronchoscopy. <i>Respiration</i> , 2021, 100, 600-610.	2.6	0
36	The Primary Ciliary Dyskinesia Computed Tomography Score in Adults with Bronchiectasis: A Derivation und Validation Study. <i>Respiration</i> , 2021, 100, 499-509.	2.6	3

#	ARTICLE	IF	CITATIONS
37	Deterioration and Mortality Risk of COPD Patients Not Fitting into Standard GOLD Categories: Results of the COSYCONET Cohort. <i>Respiration</i> , 2021, 100, 308-317.	2.6	5
38	SP-D Serum Levels Reveal Distinct Epithelial Damage in Direct Human ARDS. <i>Journal of Clinical Medicine</i> , 2021, 10, 737.	2.4	9
39	Preventing cardiovascular events after pneumonia with aspirin: one step forward, but still many to go. <i>European Respiratory Journal</i> , 2021, 57, 2003778.	6.7	2
40	A Novel Mouse Monoclonal Antibody C42 against C-Terminal Peptide of Alpha-1-Antitrypsin. <i>International Journal of Molecular Sciences</i> , 2021, 22, 2141.	4.1	0
41	COVID-19 immune signatures reveal stable antiviral T cell function despite declining humoral responses. <i>Immunity</i> , 2021, 54, 340-354.e6.	14.3	177
42	Potential Roles of Acute Phase Proteins in Cancer: Why Do Cancer Cells Produce or Take Up Exogenous Acute Phase Protein Alpha1-Antitrypsin?. <i>Frontiers in Oncology</i> , 2021, 11, 622076.	2.8	16
43	Alpha-1 antitrypsin deficiency impairs lung antibacterial immunity in mice. <i>JCI Insight</i> , 2021, 6, .	5.0	12
44	Pharmacokinetics of Meropenem in People with Cystic Fibrosis – A Proof of Concept Clinical Trial. <i>Antibiotics</i> , 2021, 10, 292.	3.7	1
45	Current evidence for COVID-19 therapies: a systematic literature review. <i>European Respiratory Review</i> , 2021, 30, 200384.	7.1	37
46	Quantification of dual-energy CT-derived functional parameters as potential imaging markers for progression of idiopathic pulmonary fibrosis. <i>European Radiology</i> , 2021, 31, 6640-6651.	4.5	12
47	Circulating cardiovascular microRNAs in critically ill COVID-19 patients. <i>European Journal of Heart Failure</i> , 2021, 23, 468-475.	7.1	107
48	Onset of effect and impact on health-related quality of life, exacerbation rate, lung function, and nasal polyposis symptoms for patients with severe eosinophilic asthma treated with benralizumab (ANDHI): a randomised, controlled, phase 3b trial. <i>Lancet Respiratory Medicine</i> , 2021, 9, 260-274.	10.7	102
49	Inhibition of Caspase-1 with Tetracycline Ameliorates Acute Lung Injury. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2021, 204, 53-63.	5.6	45
50	Dupilumab Improves Asthma Control and Lung Function in Patients with Insufficient Outcome During Previous Antibody Therapy. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2021, 9, 1177-1185.e4.	3.8	43
51	Management of hospitalised adults with coronavirus disease 2019 (COVID-19): a European Respiratory Society living guideline. <i>European Respiratory Journal</i> , 2021, 57, 2100048.	6.7	152
52	Conservative management of COVID-19 associated hypoxaemia. <i>ERJ Open Research</i> , 2021, 7, 00113-2021.	2.6	4
53	Lung microbiome composition and bronchial epithelial gene expression in patients with COPD versus healthy individuals: a bacterial 16S rRNA gene sequencing and host transcriptomic analysis. <i>Lancet Microbe</i> , 2021, 2, e300-e310.	7.3	60
54	Treatment of COPD Groups GOLD A and B with Inhaled Corticosteroids in the COSYCONET Cohort – Determinants and Consequences. <i>International Journal of COPD</i> , 2021, Volume 16, 987-998.	2.3	9

#	ARTICLE	IF	CITATIONS
55	The NLRP3-Inflammasome-Caspase-1 Pathway Is Upregulated in Idiopathic Pulmonary Fibrosis and Acute Exacerbations and Is Inducible by Apoptotic A549 Cells. <i>Frontiers in Immunology</i> , 2021, 12, 642855.	4.8	27
56	Liver-first strategy for a combined lung and liver transplant in patients with cystic fibrosis. <i>European Journal of Cardio-thoracic Surgery</i> , 2021, 60, 822-830.	1.4	2
57	Polymerization of misfolded Z alpha-1 antitrypsin protein lowers CX3CR1 expression in human PBMCs. <i>ELife</i> , 2021, 10, .	6.0	4
58	Major differences in ICU admissions during the first and second COVID-19 wave in Germany. <i>Lancet Respiratory Medicine</i> , 2021, 9, e47-e48.	10.7	104
59	Chronic airflow obstruction and ambient particulate air pollution. <i>Thorax</i> , 2021, 76, 1236-1241.	5.6	7
60	Between inflammation and thrombosis: endothelial cells in COVID-19. <i>European Respiratory Journal</i> , 2021, 58, 2100377.	6.7	86
61	Efficacy and safety of ceftobiprole in patients aged 65 years or older: a post hoc analysis of three Phase III studies. <i>Future Microbiology</i> , 2021, 16, 543-555.	2.0	5
62	Duration of antibiotic treatment using procalcitonin-guided treatment algorithms in older patients: a patient-level meta-analysis from randomized controlled trials. <i>Age and Ageing</i> , 2021, 50, 1546-1556.	1.6	6
63	C-reactive protein and procalcitonin for antimicrobial stewardship in COVID-19. <i>Infection</i> , 2021, 49, 935-943.	4.7	76
64	Pirfenidone in patients with progressive fibrotic interstitial lung diseases other than idiopathic pulmonary fibrosis (RELIEF): a double-blind, randomised, placebo-controlled, phase 2b trial. <i>Lancet Respiratory Medicine</i> , 2021, 9, 476-486.	10.7	254
65	Gender specific airway gene expression in COPD sub-phenotypes supports a role of mitochondria and of different types of leukocytes. <i>Scientific Reports</i> , 2021, 11, 12848.	3.3	8
66	Shifting the paradigm: unilateral infiltrates and ARDS?. <i>European Respiratory Journal</i> , 2021, 57, 2100043.	6.7	2
67	Computed Tomography in Adults with Bronchiectasis and Nontuberculous Mycobacterial Pulmonary Disease: Typical Imaging Findings. <i>Journal of Clinical Medicine</i> , 2021, 10, 2736.	2.4	5
68	Measurement of urinary Dickkopf-3 uncovered silent progressive kidney injury in patients with chronic obstructive pulmonary disease. <i>Kidney International</i> , 2021, 100, 1081-1091.	5.2	10
69	Boosted Pro-Inflammatory Activity in Human PBMCs by Lipopolysaccharide and SARS-CoV-2 Spike Protein Is Regulated by α -1 Antitrypsin. <i>International Journal of Molecular Sciences</i> , 2021, 22, 7941.	4.1	10
70	Scent dog identification of SARS-CoV-2 infections in different body fluids. <i>BMC Infectious Diseases</i> , 2021, 21, 707.	2.9	24
71	Real-World Multicenter Experience with Mepolizumab and Benralizumab in the Treatment of Uncontrolled Severe Eosinophilic Asthma Over 12 Months. <i>Journal of Asthma and Allergy</i> , 2021, Volume 14, 863-871.	3.4	23
72	Impact of the COVID-19 pandemic on the behaviour and health status of patients with COPD: results from the German COPD cohort COSYCONET. <i>ERJ Open Research</i> , 2021, 7, 00242-2021.	2.6	8

#	ARTICLE	IF	CITATIONS
73	COPD maintenance medication is linked to left atrial size: Results from the COSYCONET cohort. Respiratory Medicine, 2021, 185, 106461.	2.9	14
74	Prediction of lung emphysema in COPD by spirometry and clinical symptoms: results from COSYCONET. Respiratory Research, 2021, 22, 242.	3.6	7
75	Fosfomycin single- and multiple-dose pharmacokinetics in patients undergoing prolonged intermittent renal replacement therapy. Journal of Antimicrobial Chemotherapy, 2021, 77, 169-173.	3.0	2
76	Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock 2021. Critical Care Medicine, 2021, 49, e1063-e1143.	0.9	927
77	Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021. Intensive Care Medicine, 2021, 47, 1181-1247.	8.2	1,503
78	Alpha 1 Antitrypsin Therapy in Patients with Alpha 1 Antitrypsin Deficiency: Perspectives from a Registry Study and Practical Considerations for Self-Administration During the COVID-19 Pandemic. International Journal of COPD, 2021, Volume 16, 2983-2996.	2.3	8
79	Effects of therapeutic plasma exchange on the endothelial glycocalyx in septic shock. Intensive Care Medicine Experimental, 2021, 9, 57.	1.9	13
80	Discrimination of SARS-CoV-2 Infections From Other Viral Respiratory Infections by Scent Detection Dogs. Frontiers in Medicine, 2021, 8, 749588.	2.6	17
81	Î±1-Antitrypsin attenuates acute rejection of orthotopic murine lung allografts. Respiratory Research, 2021, 22, 295.	3.6	4
82	Lower Prevalence of Osteoporosis in Patients with COPD Taking Anti-Inflammatory Compounds for the Treatment of Diabetes: Results from COSYCONET. International Journal of COPD, 2021, Volume 16, 3189-3199.	2.3	5
83	Silent Hypoxia in COVID-19: A Case Series. Respiration, 2021, , 1-5.	2.6	3
84	Economic analysis of ceftaroline fosamil for treating community-acquired pneumonia in Spain. Journal of Medical Economics, 2020, 23, 148-155.	2.1	1
85	Rate and Predictors of Bacteremia in Afebrile Community-Acquired Pneumonia. Chest, 2020, 157, 529-539.	0.8	20
86	Anti-IL5 and anti-IL5RÎ± therapy for clinically significant bronchiectasis with eosinophilic endotype: a case series. European Respiratory Journal, 2020, 55, 1901333.	6.7	42
87	Time-updated resting heart rate predicts mortality in patients with COPD. Clinical Research in Cardiology, 2020, 109, 776-786.	3.3	11
88	High-sensitivity troponin I and all-cause mortality in patients with stable COPD: an analysis of the COSYCONET study. European Respiratory Journal, 2020, 55, 1901314.	6.7	26
89	Generation of a NKX2.1 â€“ p63 double transgenic knock-in reporter cell line from human induced pluripotent stem cells (MHHi006-A-4). Stem Cell Research, 2020, 42, 101659.	0.7	4
90	Pneumococcal conjugate serotype distribution and predominating role of serotype 3 in German adults with community-acquired pneumonia. Vaccine, 2020, 38, 1129-1136.	3.8	28

#	ARTICLE	IF	CITATIONS
91	Relationship between clinical and radiological signs of bronchiectasis in COPD patients: Results from COSYCONET. <i>Respiratory Medicine</i> , 2020, 172, 106117.	2.9	4
92	Reappearance of effector T cells is associated with recovery from COVID-19. <i>EBioMedicine</i> , 2020, 57, 102885.	6.1	109
93	<p></p>Switch from IL-5 to IL-5-Receptor \pm Antibody Treatment in Severe Eosinophilic Asthma<p></p>. <i>Journal of Asthma and Allergy</i> , 2020, Volume 13, 605-614.	3.4	30
94	Overexpression of Macrophage-Inducible C-Type Lectin Mincle Aggravates Proinflammatory Responses to <i>Streptococcus pneumoniae</i> with Fatal Outcome in Mice. <i>Journal of Immunology</i> , 2020, 205, 3390-3399.	0.8	7
95	Enoximone in status asthmaticus. <i>ERJ Open Research</i> , 2020, 6, 00367-2019.	2.6	4
96	Scent dog identification of samples from COVID-19 patients – a pilot study. <i>BMC Infectious Diseases</i> , 2020, 20, 536.	2.9	132
97	The Delivery of \pm 1-Antitrypsin Therapy Through Transepidermal Route: Worthwhile to Explore. <i>Frontiers in Pharmacology</i> , 2020, 11, 983.	3.5	9
98	Case characteristics, resource use, and outcomes of 10 \pm 21 patients with COVID-19 admitted to 920 German hospitals: an observational study. <i>Lancet Respiratory Medicine</i> , the, 2020, 8, 853-862.	10.7	628
99	Chronic Obstructive Pulmonary Disease and Lung Transplantation. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2020, 41, 862-873.	2.1	1
100	Prediction of air trapping or pulmonary hyperinflation by forced spirometry in COPD patients: results from COSYCONET. <i>ERJ Open Research</i> , 2020, 6, 00092-2020.	2.6	16
101	Benefits of pulmonary rehabilitation in patients with advanced lymphangioleiomyomatosis (LAM) compared with COPD – a retrospective analysis. <i>Orphanet Journal of Rare Diseases</i> , 2020, 15, 255.	2.7	6
102	Real-world mepolizumab in the prospective severe asthma REALITI-A study: initial analysis. <i>European Respiratory Journal</i> , 2020, 56, 2000151.	6.7	84
103	Injury to the Endothelial Glycocalyx in Critically Ill Patients with COVID-19. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2020, 202, 1178-1181.	5.6	89
104	World Lung Day: what, why, and where to?. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 2020, 319, L527-L533.	2.9	6
105	Recurrent Life-threatening Pneumonitis in a 37-Year-Old Woman. <i>Chest</i> , 2020, 158, e127-e132.	0.8	0
106	Generation of two hiPSC clones (MHHi019-A, MHHi019-B) from a primary ciliary dyskinesia patient carrying a homozygous deletion in the NME5 gene (c.415delA (p.Ile139Tyrfs*8)). <i>Stem Cell Research</i> , 2020, 48, 101988.	0.7	7
107	<p>Plasma Acute Phase Proteins as Predictors of Chronic Lung Allograft Dysfunction in Lung Transplant Recipients</p>. <i>Journal of Inflammation Research</i> , 2020, Volume 13, 1021-1028.	3.5	5
108	<p></p>Impact of Education on COPD Severity and All-Cause Mortality in Lifetime Never-Smokers and Longtime Ex-Smokers: Results of the COSYCONET Cohort<p></p>. <i>International Journal of COPD</i> , 2020, Volume 15, 2787-2798.	2.3	13

#	ARTICLE	IF	CITATIONS
109	Survival and course of lung function in the presence or absence of antifibrotic treatment in patients with idiopathic pulmonary fibrosis: long-term results of the INSIGHTS-IPF registry. <i>European Respiratory Journal</i> , 2020, 56, 1902279.	6.7	102
110	Generation of two hiPSC lines (MHHi016-A, MHHi016-B) from a primary ciliary dyskinesia patient carrying a homozygous 5Åbp duplication (c.248_252dup (p.Gly85Cysfs*11)) in exon 1 of the CCNO gene. <i>Stem Cell Research</i> , 2020, 46, 101850.	0.7	4
111	Generation of two human induced pluripotent stem cell lines (MHHi017-A, MHHi017-B) from a patient with primary ciliary dyskinesia carrying a homozygous mutation (c.7915CÀ>ÀT [p.Arg2639*]) in the DNAH5 gene. <i>Stem Cell Research</i> , 2020, 46, 101848.	0.7	4
112	Pulmonary Vascular Endothelialitis, Thrombosis, and Angiogenesis in Covid-19. <i>New England Journal of Medicine</i> , 2020, 383, 120-128.	27.0	4,442
113	Alpha1-antitrypsin protects lung cancer cells from staurosporine-induced apoptosis: the role of bacterial lipopolysaccharide. <i>Scientific Reports</i> , 2020, 10, 9563.	3.3	13
114	Expanding the spectrum of European Respiratory Society official scientific documents: short documents complement clinical practice guidelines, statements and technical standards. <i>European Respiratory Journal</i> , 2020, 55, 2001030.	6.7	3
115	Treatment of Community-Acquired Pneumonia in Immunocompromised Adults. <i>Chest</i> , 2020, 158, 1896-1911.	0.8	105
116	Morphomolecular motifs of pulmonary neoangiogenesis in interstitial lung diseases. <i>European Respiratory Journal</i> , 2020, 55, 1900933.	6.7	51
117	Regulatory T Cells Limit Pneumococcus-Induced Exacerbation of Lung Fibrosis in Mice. <i>Journal of Immunology</i> , 2020, 204, 2429-2438.	0.8	18
118	Effect of therapeutic plasma exchange on endothelial activation and coagulation-related parameters in septic shock. <i>Critical Care</i> , 2020, 24, 71.	5.8	36
119	Extracorporeal cytokine removal in severe CAR-T cell associated cytokine release syndrome. <i>Journal of Critical Care</i> , 2020, 57, 124-129.	2.2	25
120	<p>Onset of Effect, Changes in Airflow Obstruction and Lung Volume, and Health-Related Quality of Life Improvements with Benralizumab for Patients with Severe Eosinophilic Asthma: Phase IIIb Randomized, Controlled Trial (SOLANA)</p>. <i>Journal of Asthma and Allergy</i> , 2020, Volume 13, 115-126.	3.4	30
121	Respiratory medicine is not gender blind. <i>European Respiratory Journal</i> , 2020, 55, 1901847.	6.7	8
122	The NLRP3 inflammasome pathway is activated in sarcoidosis and involved in granuloma formation. <i>European Respiratory Journal</i> , 2020, 55, 1900119.	6.7	51
123	Serum Levels of Alpha1-antitrypsin and Their Relationship With COPD in the General Spanish Population. <i>Archivos De Bronconeumologia</i> , 2020, 56, 76-83.	0.8	22
124	Long-term outcomes after intraoperative extracorporeal membrane oxygenation during lung transplantation. <i>Journal of Heart and Lung Transplantation</i> , 2020, 39, 915-925.	0.6	28
125	Invasive and Non-Invasive Ventilation in Patients With COVID-19. <i>Deutsches A&#x0308;rztblatt International</i> , 2020, 117, 528-533.	0.9	40
126	Procalcitonin to initiate or discontinue antibiotics in acute respiratory tract infections. <i>The Cochrane Library</i> , 2019, 2019, CD007498.	2.8	320

#	ARTICLE	IF	CITATIONS
127	Ceftaroline fosamil as a potential treatment option for <i>Staphylococcus aureus</i> community-acquired pneumonia in adults. <i>International Journal of Antimicrobial Agents</i> , 2019, 54, 410-422.	2.5	33
128	Morphological and molecular motifs of fibrosing pulmonary injury patterns. <i>Journal of Pathology: Clinical Research</i> , 2019, 5, 256-271.	3.0	16
129	SERPINA1 gene polymorphisms in a population-based ALSPAC cohort. <i>Pediatric Pulmonology</i> , 2019, 54, 1474-1478.	2.0	6
130	<p></p>Adherence To Respiratory And Nonrespiratory Medication In Patients With COPD: Results Of The German COSYCONET Cohort<p></p>. <i>Patient Preference and Adherence</i> , 2019, Volume 13, 1711-1721.	1.8	10
131	CAT score single item analysis in patients with COPD: Results from COSYCONET. <i>Respiratory Medicine</i> , 2019, 159, 105810.	2.9	16
132	Maintenance Immunosuppression Is Associated With Better Outcome in the 2017/2018 Influenza Epidemic. <i>Open Forum Infectious Diseases</i> , 2019, 6, ofz381.	0.9	2
133	Clinical Significance of SERPINA1 Gene and Its Encoded Alpha1-antitrypsin Protein in NSCLC. <i>Cancers</i> , 2019, 11, 1306.	3.7	52
134	Increasing bronchiectasis prevalence in Germany, 2009â€“2017: a population-based cohort study. <i>European Respiratory Journal</i> , 2019, 54, 1900499.	6.7	33
135	Macrolide combination therapy for patients hospitalised with community-acquired pneumonia? An individualised approach supported by machine learning. <i>European Respiratory Journal</i> , 2019, 54, 1900824.	6.7	20
136	Invasive mould infections in solid organ transplant patients: modifiers and indicators of disease and treatment response. <i>Infection</i> , 2019, 47, 919-927.	4.7	17
137	Risk factors and outcomes of vocal cord paralysis after lung transplantation - a retrospective cohort study. <i>Transplant International</i> , 2019, 32, 626-634.	1.6	3
138	<i>M. pneumoniae</i> and <i>C. pneumoniae</i> are no relevant pathogens in critically ill patients with hospital-acquired respiratory tract infections. <i>Infection</i> , 2019, 47, 471-474.	4.7	11
139	PCR-based routine diagnostics uncover hidden burden of Legionnaires' disease. <i>Lancet Infectious Diseases</i> , The, 2019, 19, 681-683.	9.1	2
140	MRIâ€“derived regional flowâ€“volume loop parameters detect earlyâ€“stage chronic lung allograft dysfunction. <i>Journal of Magnetic Resonance Imaging</i> , 2019, 50, 1873-1882.	3.4	33
141	Extracorporeal membrane oxygenation for acute respiratory distress syndrome due to <i>Pneumocystis</i> pneumonia. <i>European Respiratory Journal</i> , 2019, 54, 1900410.	6.7	7
142	Valuing antibiotics: The role of the hospital clinician. <i>International Journal of Antimicrobial Agents</i> , 2019, 54, 16-22.	2.5	1
143	The FMS-like tyrosine kinase-3 ligand/lung dendritic cell axis contributes to regulation of pulmonary fibrosis. <i>Thorax</i> , 2019, 74, 947-957.	5.6	24
144	Ten tips for the intensive care management of transplanted lung patients. <i>Intensive Care Medicine</i> , 2019, 45, 371-373.	8.2	3

#	ARTICLE	IF	CITATIONS
145	Early improvement in severely ill patients with pneumonia treated with ceftobiprole: a retrospective analysis of two major trials. BMC Infectious Diseases, 2019, 19, 195.	2.9	18
146	Procalcitonin (PCT)-guided antibiotic stewardship: an international experts consensus on optimized clinical use. Clinical Chemistry and Laboratory Medicine, 2019, 57, 1308-1318.	2.3	182
147	Effect of COPD severity and comorbidities on the result of the PHQ-9 tool for the diagnosis of depression: results from the COSYCONET cohort study. Respiratory Research, 2019, 20, 30.	3.6	26
148	The association of cognitive functioning as measured by the DemTect with functional and clinical characteristics of COPD: results from the COSYCONET cohort. Respiratory Research, 2019, 20, 257.	3.6	13
149	High degree of polyclonality hinders somatic mutation calling in lung brush samples of COPD cases and controls. Scientific Reports, 2019, 9, 20158.	3.3	1
150	Adherence is associated with a favorable outcome after lung transplantation. PLoS ONE, 2019, 14, e0226167.	2.5	19
151	Chronic progressive pulmonary paracoccidioidomycosis in a female immigrant from Venezuela. Therapeutic Advances in Respiratory Disease, 2019, 13, 175346661989491.	2.6	5
152	Long-term safety and efficacy of benralizumab in patients with severe, uncontrolled asthma: 1-year results from the BORA phase 3 extension trial. Lancet Respiratory Medicine, the, 2019, 7, 46-59.	10.7	216
153	Single- and multiple-dose pharmacokinetics and total removal of colistin in critically ill patients with acute kidney injury undergoing prolonged intermittent renal replacement therapy. Journal of Antimicrobial Chemotherapy, 2019, 74, 997-1002.	3.0	11
154	Effect of Indacaterol/Glycopyrronium on Pulmonary Perfusion and Ventilation in Hyperinflated Patients with Chronic Obstructive Pulmonary Disease (CLAIM). A Double-Blind, Randomized, Crossover Trial. American Journal of Respiratory and Critical Care Medicine, 2019, 199, 1086-1096.	5.6	55
155	Comparison of quantitative regional perfusion-weighted phase resolved functional lung (PREFUL) MRI with dynamic gadolinium-enhanced regional pulmonary perfusion MRI in COPD patients. Journal of Magnetic Resonance Imaging, 2019, 49, 1122-1132.	3.4	36
156	Effect of lung deflation with indacaterol plus glycopyrronium on ventricular filling in patients with hyperinflation and COPD (CLAIM): a double-blind, randomised, crossover, placebo-controlled, single-centre trial. Lancet Respiratory Medicine, the, 2018, 6, 368-378.	10.7	137
157	Targeting intracellular signaling as an antiviral strategy: aerosolized LASAG for the treatment of influenza in hospitalized patients. Emerging Microbes and Infections, 2018, 7, 1-8.	6.5	22
158	Airway obstruction and lung hyperinflation in COPD are linked to an impaired left ventricular diastolic filling. Respiratory Medicine, 2018, 137, 14-22.	2.9	35
159	Left ventricular volume and wall stress are linked to lung function impairment in COPD. International Journal of Cardiology, 2018, 261, 172-178.	1.7	27
160	Effect of antifibrotics on short-term outcome after bilateral lung transplantation: a multicentre analysis. European Respiratory Journal, 2018, 51, 1800503.	6.7	21
161	Efficacy and safety of trimodulin, a novel polyclonal antibody preparation, in patients with severe community-acquired pneumonia: a randomized, placebo-controlled, double-blind, multicenter, phase II trial (CIGMA study). Intensive Care Medicine, 2018, 44, 438-448.	8.2	96
162	Burden of pneumococcal community-acquired pneumonia in adults across Europe: A literature review. Respiratory Medicine, 2018, 137, 6-13.	2.9	90

#	ARTICLE	IF	CITATIONS
163	Self-reported non-adherence to immunosuppressive medication in adult lung transplant recipients: A single-center cross-sectional study. <i>Clinical Transplantation</i> , 2018, 32, e13214.	1.6	14
164	Microbiologic Outcome of Interventions Against Mycobacterium avium Complex Pulmonary Disease. <i>Chest</i> , 2018, 153, 888-921.	0.8	102
165	Infection transmission among lung transplant couples. <i>Transplant Infectious Disease</i> , 2018, 20, e12853.	1.7	3
166	New era for European Respiratory Society clinical practice guidelines: joining efficiency and high methodological standards. <i>European Respiratory Journal</i> , 2018, 51, 1800221.	6.7	23
167	Effect of procalcitonin-guided antibiotic treatment on mortality in acute respiratory infections: a patient level meta-analysis. <i>Lancet Infectious Diseases</i> , The, 2018, 18, 95-107.	9.1	337
168	Free-breathing Dynamic 19F Gas MR Imaging for Mapping of Regional Lung Ventilation in Patients with COPD. <i>Radiology</i> , 2018, 286, 1040-1051.	7.3	54
169	The revised GOLD 2017 COPD categorization in relation to comorbidities. <i>Respiratory Medicine</i> , 2018, 134, 79-85.	2.9	45
170	Adenoviral vector-mediated GM-CSF gene transfer improves anti-mycobacterial immunity in mice – role of regulatory T cells. <i>Immunobiology</i> , 2018, 223, 331-341.	1.9	3
171	<sc>DNA</sc>-based testing in lung transplant recipients with suspected non-viral lower respiratory tract infection: A prospective observational study. <i>Transplant Infectious Disease</i> , 2018, 20, e12811.	1.7	6
172	Comparison of quantitative regional ventilation-weighted fourier decomposition MRI with dynamic fluorinated gas washout MRI and lung function testing in COPD patients. <i>Journal of Magnetic Resonance Imaging</i> , 2018, 47, 1534-1541.	3.4	35
173	Clinical course, treatment and outcome of Pneumocystis pneumonia in immunocompromised adults: a retrospective analysis over 17 years. <i>Critical Care</i> , 2018, 22, 307.	5.8	81
174	The European Respiratory Society's 10 Principles for Lung Health. <i>European Respiratory Journal</i> , 2018, 52, 1801373.	6.7	6
175	The European Multicentre Bronchiectasis Audit and Research Collaboration (EMBARC) ERS Clinical Research Collaboration. <i>European Respiratory Journal</i> , 2018, 52, 1802074.	6.7	26
176	ERS Clinical Research Collaborations: underpinning research excellence. <i>European Respiratory Journal</i> , 2018, 52, 1801534.	6.7	39
177	Comparison of quantitative regional ventilation-weighted fourier decomposition MRI with dynamic fluorinated gas washout MRI and lung function testing in COPD patients. <i>Journal of Magnetic Resonance Imaging</i> , 2018, 47, spcone-spcone.	3.4	0
178	Early therapeutic plasma exchange in septic shock: a prospective open-label nonrandomized pilot study focusing on safety, hemodynamics, vascular barrier function, and biologic markers. <i>Critical Care</i> , 2018, 22, 285.	5.8	113
179	The European Respiratory Society: ensuring excellence through education best practice. <i>European Respiratory Journal</i> , 2018, 52, 1801248.	6.7	2
180	The burden of sinus disease in cystic fibrosis lung transplant recipients. <i>Transplant Infectious Disease</i> , 2018, 20, e12924.	1.7	25

#	ARTICLE	IF	CITATIONS
181	Procalcitonin-guided antibiotic therapy algorithms for different types of acute respiratory infections based on previous trials. Expert Review of Anti-Infective Therapy, 2018, 16, 555-564.	4.4	41
182	The Multifaceted Effects of Alpha1-Antitrypsin on Neutrophil Functions. Frontiers in Pharmacology, 2018, 9, 341.	3.5	93
183	Anti-IL-5 therapy in patients with severe eosinophilic asthma – clinical efficacy and possible criteria for treatment response. BMC Pulmonary Medicine, 2018, 18, 119.	2.0	96
184	Uric acid, lung function, physical capacity and exacerbation frequency in patients with COPD: a multi-dimensional approach. Respiratory Research, 2018, 19, 110.	3.6	35
185	Computed tomography in adult patients with primary ciliary dyskinesia: Typical imaging findings. PLoS ONE, 2018, 13, e0191457.	2.5	23
186	Dual bronchodilation in COPD: lung function and patient-reported outcomes – a review. International Journal of COPD, 2017, Volume 12, 141-168.	2.3	26
187	The unusual journey of a tooth. Found but not lost?. Clinical Respiratory Journal, 2017, 11, 267-268.	1.6	0
188	Time to follow up when comparing studies of pneumococcal vaccines. Lancet Infectious Diseases, The, 2017, 17, 244-246.	9.1	2
189	Comparative analysis of morphological and molecular motifs in bronchiolitis obliterans and alveolar fibroelastosis after lung and stem cell transplantation. Journal of Pathology: Clinical Research, 2017, 3, 17-28.	3.0	35
190	The intensive care medicine research agenda on multidrug-resistant bacteria, antibiotics, and stewardship. Intensive Care Medicine, 2017, 43, 1187-1197.	8.2	103
191	Response. Chest, 2017, 151, 517-518.	0.8	0
192	A randomized placebo-controlled phase II study of a Pseudomonas vaccine in ventilated ICU patients. Critical Care, 2017, 21, 22.	5.8	77
193	Role of dual bronchodilators in COPD: A review of the current evidence for indacaterol/glycopyrronium. Pulmonary Pharmacology and Therapeutics, 2017, 45, 19-33.	2.6	20
194	Response. Chest, 2017, 151, 1178-1179.	0.8	1
195	Outcome of acute respiratory distress syndrome in university and non-university hospitals in Germany. Critical Care, 2017, 21, 122.	5.8	28
196	Cellular analysis in bronchoalveolar lavage: inherent limitations of current standard procedure. European Respiratory Journal, 2017, 49, 1601844.	6.7	13
197	Pulmonary exacerbation in adults with bronchiectasis: a consensus definition for clinical research. European Respiratory Journal, 2017, 49, 1700051.	6.7	253
198	Mid-term results of bilateral lung transplant with postoperatively extended intraoperative extracorporeal membrane oxygenation for severe pulmonary hypertension. European Journal of Cardio-thoracic Surgery, 2017, 52, 163-170.	1.4	48

#	ARTICLE	IF	CITATIONS
199	European Respiratory Society guidelines for the management of adult bronchiectasis. European Respiratory Journal, 2017, 50, 1700629.	6.7	788
200	Impact of alpha 1-antitrypsin deficiency and prior augmentation therapy on patients' survival after lung transplantation. European Respiratory Journal, 2017, 50, 1700962.	6.7	10
201	Pneumonia and the Risk of Cardiovascular Death. Time to Change Our Strategy. American Journal of Respiratory and Critical Care Medicine, 2017, 196, 541-543.	5.6	6
202	Taken to task: what is and is not an appropriate response to an ERS guidelines task force?. European Respiratory Journal, 2017, 50, 1700952.	6.7	1
203	Alpha1-antitrypsin binds hemin and prevents oxidative activation of human neutrophils: putative pathophysiological significance. Journal of Leukocyte Biology, 2017, 102, 1127-1141.	3.3	41
204	Comparison of exercise training responses in COPD patients with and without Alpha-1 antitrypsin deficiency. Respiratory Medicine, 2017, 130, 98-101.	2.9	13
205	More on idiopathic pulmonary arterial hypertension with a low diffusing capacity. European Respiratory Journal, 2017, 50, 1700354.	6.7	25
206	Intensive care unit patients with lower respiratory tract nosocomial infections: the ENIRRI project. ERJ Open Research, 2017, 3, 00092-2017.	2.6	22
207	Management of Respiratory Infections with Use of Procalcitonin: Moving toward More Personalized Antibiotic Treatment Decisions. ACS Infectious Diseases, 2017, 3, 875-879.	3.8	13
208	CT at onset of chronic lung allograft dysfunction in lung transplant patients predicts development of the restrictive phenotype and survival. European Journal of Radiology, 2017, 94, 78-84.	2.6	23
209	Effects of procalcitonin testing on antibiotic use and clinical outcomes in patients with upper respiratory tract infections. An individual patient data meta-analysis. Clinical Chemistry and Laboratory Medicine, 2017, 56, 170-177.	2.3	17
210	Peripheral Artery Disease and Its Clinical Relevance in Patients with Chronic Obstructive Pulmonary Disease in the COPD and Systemic Consequencesâ€“Comorbidities Network Study. American Journal of Respiratory and Critical Care Medicine, 2017, 195, 189-197.	5.6	81
211	Cardiovascular risk in patients with alpha-1-antitrypsin deficiency. Respiratory Research, 2017, 18, 171.	3.6	27
212	Characteristics and provision of care of patients with the acute respiratory distress syndrome: descriptive findings from the DCAPO cohort baseline and comparison with international findings. Journal of Thoracic Disease, 2017, 9, 818-830.	1.4	12
213	Does urinary peptide content differ between COPD patients with and without inherited alpha-1 antitrypsin deficiency?. International Journal of COPD, 2017, Volume 12, 829-837.	2.3	12
214	Health related quality of life in patients with idiopathic pulmonary fibrosis in clinical practice: insights-IPF registry. Respiratory Research, 2017, 18, 139.	3.6	135
215	Therapy preferences of patients with lung and colon cancer: a discrete choice experiment. Patient Preference and Adherence, 2017, Volume 11, 1647-1656.	1.8	18
216	Plasminogen activator inhibitor-1 is elevated in patients with COPD independent of metabolic and cardiovascular function. International Journal of COPD, 2017, Volume 12, 981-987.	2.3	26

#	ARTICLE	IF	CITATIONS
217	Influence of lung CT changes in chronic obstructive pulmonary disease (COPD) on the human lung microbiome. PLoS ONE, 2017, 12, e0180859.	2.5	33
218	Advances in the prevention, management, and treatment of community-acquired pneumonia. F1000Research, 2016, 5, 300.	1.6	26
219	Î±-Linoleic Acid Enhances the Capacity of Î±1-Antitrypsin to Inhibit Lipopolysaccharide-Induced IL-1Î² in Human Blood Neutrophils. Molecular Medicine, 2016, 22, 680-693.	4.4	25
220	Topical Nasal Anesthesia in Flexible Bronchoscopy – A Cross-Over Comparison between Two Devices. PLoS ONE, 2016, 11, e0150905.	2.5	3
221	Emphysema- and airway-dominant COPD phenotypes defined by standardised quantitative computed tomography. European Respiratory Journal, 2016, 48, 92-103.	6.7	46
222	Lung transplantation for non-cystic fibrosis bronchiectasis. Respiratory Medicine, 2016, 115, 60-65.	2.9	26
223	Can we improve clinical outcomes in patients with pneumonia treated with antibiotics in the intensive care unit?. Expert Review of Respiratory Medicine, 2016, 10, 907-918.	2.5	10
224	Current thinking and new paradigm for COPD. Respiratory Medicine, 2016, 112, 126-127.	2.9	1
225	The German COPD cohort COSYCONET: Aims, methods and descriptive analysis of the study population at baseline. Respiratory Medicine, 2016, 114, 27-37.	2.9	113
226	Impact of pneumococcal vaccination in children on serotype distribution in adult community-acquired pneumonia using the serotype-specific multiplex urinary antigen detection assay. Vaccine, 2016, 34, 2342-2348.	3.8	31
227	Why do some adults with PiMZ Î±1-antitrypsin develop bronchiectasis?. ERJ Open Research, 2016, 2, 00021-2016.	2.6	5
228	Associations between ventilator settings during extracorporeal membrane oxygenation for refractory hypoxemia and outcome in patients with acute respiratory distress syndrome: a pooled individual patient data analysis. Intensive Care Medicine, 2016, 42, 1672-1684.	8.2	176
229	Lung transplantation in the spotlight: Reasons for high-cost procedures. Journal of Heart and Lung Transplantation, 2016, 35, 1227-1236.	0.6	10
230	Different Training-Induced Skeletal Muscle Adaptations in COPD Patients with and without Alpha-1 Antitrypsin Deficiency. Respiration, 2016, 92, 339-347.	2.6	22
231	Well-Known and Less Well-Known Functions of Alpha-1 Antitrypsin. Its Role in Chronic Obstructive Pulmonary Disease and Other Disease Developments. Annals of the American Thoracic Society, 2016, 13, S280-S288.	3.2	94
232	Costs and outcomes of the German disease management programme (DMP) for chronic obstructive pulmonary disease (COPD) – A large population-based cohort study. Health Policy, 2016, 120, 1029-1039.	3.0	28
233	Comparison of the qSOFA and CRB-65 for risk prediction in patients with community-acquired pneumonia. Intensive Care Medicine, 2016, 42, 2108-2110.	8.2	43
234	Pharmacokinetics and total removal of fosfomycin in two patients undergoing intermittent haemodialysis and extended dialysis: prescription needs to avoid under-dosing. Journal of Antimicrobial Chemotherapy, 2016, 71, 2673-2674.	3.0	7

#	ARTICLE	IF	CITATIONS
235	CXCL13 in idiopathic pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension. <i>Respiratory Research</i> , 2016, 17, 21.	3.6	26
236	MR Imagingâ€‘derived Regional Pulmonary Parenchymal Perfusion and Cardiac Function for Monitoring Patients with Chronic Thromboembolic Pulmonary Hypertension before and after Pulmonary Endarterectomy. <i>Radiology</i> , 2016, 279, 925-934.	7.3	54
237	New antibiotic development: the need versus the costs. <i>Lancet Infectious Diseases</i> , The, 2016, 16, 386-387.	9.1	10
238	Single- and multiple-dose pharmacokinetics of ethambutol and rifampicin in a tuberculosis patient with acute respiratory distress syndrome undergoing extended daily dialysis and ECMO treatment. <i>International Journal of Infectious Diseases</i> , 2016, 42, 1-3.	3.3	11
239	Intratracheal Administration of Antimicrobial Agents in Mechanically Ventilated Adults: An International Survey on Delivery Practices and Safety. <i>Respiratory Care</i> , 2016, 61, 1008-1014.	1.6	39
240	Community-acquired <i>Haemophilus influenzae</i> pneumonia â€‘ New insights from the CAPNETZ study. <i>Journal of Infection</i> , 2016, 72, 554-563.	3.3	21
241	The EMBARC European Bronchiectasis Registry: protocol for an international observational study. <i>ERJ Open Research</i> , 2016, 2, 00081-2015.	2.6	133
242	Diffusion Capacity and Mortality in Patients With Pulmonary Hypertension Due to Heart Failure With Preserved Ejection Fraction. <i>JACC: Heart Failure</i> , 2016, 4, 441-449.	4.1	95
243	ICU Care Before and After Lung Transplantation. <i>Chest</i> , 2016, 150, 442-450.	0.8	45
244	Should all adult cystic fibrosis patients with repeated nontuberculous mycobacteria cultures receive specific treatment? A 10-year caseâ€‘control study. <i>European Respiratory Journal</i> , 2016, 47, 1575-1577.	6.7	8
245	Nasal potential difference of carriers of the W493R ENaC variant with non-cystic fibrosis bronchiectasis. <i>European Respiratory Journal</i> , 2016, 47, 322-324.	6.7	8
246	Acute exacerbation in COPD: we must do more. <i>European Respiratory Journal</i> , 2016, 47, 14-15.	6.7	6
247	Report of the European Respiratory Society/European Cystic Fibrosis Society task force on the care of adults with cystic fibrosis. <i>European Respiratory Journal</i> , 2016, 47, 420-428.	6.7	102
248	C-type Lectin Mincle Recognizes Glucosyl-diacylglycerol of <i>Streptococcus pneumoniae</i> and Plays a Protective Role in Pneumococcal Pneumonia. <i>PLoS Pathogens</i> , 2016, 12, e1006038.	4.7	51
249	Pneumococcal Conjugate Vaccineâ€‘ Equally Effective for Everyone?. <i>Deutsches A&#x0308;rztblatt International</i> , 2016, 113, 137-8.	0.9	4
250	An international multicenter retrospective study of <i>Pseudomonas aeruginosa</i> nosocomial pneumonia: impact of multidrug resistance. <i>Critical Care</i> , 2015, 19, 219.	5.8	209
251	Predictors of Success for Pulmonary Rehabilitation in Patients Awaiting Lung Transplantation. <i>Transplantation</i> , 2015, 99, 1072-1077.	1.0	53
252	Lung Preservation With Perfadex or Celsior in Clinical Transplantation. <i>Transplantation</i> , 2015, 99, 1933-1939.	1.0	15

#	ARTICLE	IF	CITATIONS
253	High Individuality of Respiratory Bacterial Communities in a Large Cohort of Adult Cystic Fibrosis Patients under Continuous Antibiotic Treatment. PLoS ONE, 2015, 10, e0117436.	2.5	27
254	Concept for a study design in patients with severe community-acquired pneumonia: A randomised controlled trial with a novel IGM-enriched immunoglobulin preparation â€” The CIGMA study. Respiratory Medicine, 2015, 109, 758-767.	2.9	37
255	Prevention is better than cure: time to change the focus of community-acquired pneumonia management. European Respiratory Journal, 2015, 45, 1524-1525.	6.7	4
256	When a respiratory pathogen turns to the skin: cutaneous tuberculosis in a lung transplant patient. Therapeutic Advances in Respiratory Disease, 2015, 9, 260-262.	2.6	9
257	Molecular Profiling in Lung Biopsies of Human Pulmonary Allografts to Predict Chronic Lung Allograft Dysfunction. American Journal of Pathology, 2015, 185, 3178-3188.	3.8	35
258	Acute hemodynamic effects of adaptive servoventilation in patients with pre-capillary and post-capillary pulmonary hypertension. Respiratory Research, 2015, 16, 137.	3.6	9
259	Treatment of Gram-negative pneumonia in the critical care setting: is the beta-lactam antibiotic backbone broken beyond repair?. Critical Care, 2015, 20, 19.	5.8	48
260	Preemptive treatment with therapeutic plasma exchange and rituximab for early donor-specific antibodies after lung transplantation. Journal of Heart and Lung Transplantation, 2015, 34, 50-58.	0.6	37
261	Time to reconsider how we do antibiotic therapy trials. Lancet Infectious Diseases, The, 2015, 15, 132-133.	9.1	8
262	Chronic Lung Allograft Dysfunction: Oxygen-enhanced T1-Mapping MR Imaging of the Lung. Radiology, 2015, 276, 266-273.	7.3	32
263	Arginase 1 activity worsens lungâ€™s protective immunity against <i>Streptococcus pneumoniae</i> infection. European Journal of Immunology, 2015, 45, 1716-1726.	2.9	15
264	Prognostic value of procalcitonin in respiratory tract infections across clinical settings. Critical Care, 2015, 19, 74.	5.8	44
265	<i>Streptococcus pneumoniae</i> triggers progression of pulmonary fibrosis through pneumolysin. Thorax, 2015, 70, 636-646.	5.6	71
266	Community-acquired pneumonia as medical emergency: predictors of early deterioration. Thorax, 2015, 70, 551-558.	5.6	73
267	Therapeutic approach to respiratory infections in lung transplantation. Pulmonary Pharmacology and Therapeutics, 2015, 32, 149-154.	2.6	10
268	Management of patients with idiopathic pulmonary fibrosis in clinical practice: the INSIGHTS-IPF registry. European Respiratory Journal, 2015, 46, 186-196.	6.7	194
269	Veno-veno-arterial extracorporeal membrane oxygenation for respiratory failure with severe haemodynamic impairment: technique and early outcomes. Interactive Cardiovascular and Thoracic Surgery, 2015, 20, 761-767.	1.1	66
270	Allogeneic CD4+CD25high T Cells Regulate Obliterative Bronchiolitis of Heterotopic Bronchus Allografts in Both Porcinized and Humanized Mouse Models. Transplantation, 2015, 99, 482-491.	1.0	13

#	ARTICLE	IF	CITATIONS
271	Bronchiectasis in Germany: a population-based estimation of disease prevalence. <i>European Respiratory Journal</i> , 2015, 46, 1805-1807.	6.7	122
272	Pneumococcal conjugate vaccine for adults: it's tough to make predictions, isn't it? <i>European Respiratory Journal</i> , 2015, 46, 1265-1268.	6.7	4
273	Cohort Study of Airway Mycobiome in Adult Cystic Fibrosis Patients: Differences in Community Structure between Fungi and Bacteria Reveal Predominance of Transient Fungal Elements. <i>Journal of Clinical Microbiology</i> , 2015, 53, 2900-2907.	3.9	62
274	α 1-Antitrypsin Combines with Plasma Fatty Acids and Induces Angiopoietin-like Protein 4 Expression. <i>Journal of Immunology</i> , 2015, 195, 3605-3616.	0.8	47
275	Managing CAP patients at risk of clinical failure. <i>Respiratory Medicine</i> , 2015, 109, 157-169.	2.9	9
276	Performance of perfusion-weighted Fourier decomposition MRI for detection of chronic pulmonary emboli. <i>Journal of Magnetic Resonance Imaging</i> , 2015, 42, 72-79.	3.4	38
277	Macrophage-Inducible C-Type Lectin Mincle-Expressing Dendritic Cells Contribute to Control of Splenic <i>Mycobacterium bovis</i> BCG Infection in Mice. <i>Infection and Immunity</i> , 2015, 83, 184-196.	2.2	46
278	How Can We Improve the Detection of Alpha1-Antitrypsin Deficiency?. <i>PLoS ONE</i> , 2015, 10, e0135316.	2.5	16
279	Conventional vs. Tablet Computer-Based Patient Education following Lung Transplantation – A Randomized Controlled Trial. <i>PLoS ONE</i> , 2014, 9, e90828.	2.5	51
280	Cardiac Mass and Function Decrease in Bronchiolitis Obliterans Syndrome after Lung Transplantation: Relationship to Physical Activity?. <i>PLoS ONE</i> , 2014, 9, e114001.	2.5	1
281	Imaging in the Diagnosis of Lung Disease. <i>Deutsches Ärzteblatt International</i> , 2014, 111, 179-80.	0.9	7
282	Acute-Phase Protein α 1-Antitrypsin – A Novel Regulator of Angiopoietin-like Protein 4 Transcription and Secretion. <i>Journal of Immunology</i> , 2014, 192, 5354-5362.	0.8	26
283	Six simple questions contra the delay. <i>European Respiratory Journal</i> , 2014, 43, 10-11.	6.7	0
284	Dysnatremia, vasopressin, atrial natriuretic peptide and mortality in patients with community-acquired pneumonia. <i>Respiratory Medicine</i> , 2014, 108, 1696-1705.	2.9	42
285	Non-invasive positive pressure ventilation for severe COPD – Authors' reply. <i>Lancet Respiratory Medicine</i> , 2014, 2, e19.	10.7	5
286	Viral, bacterial or both? Regardless, we need to treat infection in COPD. <i>European Respiratory Journal</i> , 2014, 44, 11-13.	6.7	15
287	Safety and efficacy of outpatient bronchoscopy in lung transplant recipients - a single centre analysis of 3,197 procedures. <i>Transplantation Research</i> , 2014, 3, 11.	1.5	30
288	Non-invasive positive pressure ventilation for the treatment of severe stable chronic obstructive pulmonary disease: a prospective, multicentre, randomised, controlled clinical trial. <i>Lancet Respiratory Medicine</i> , 2014, 2, 698-705.	10.7	594

#	ARTICLE	IF	CITATIONS
289	Î±1-Antitrypsin (AAT)â€“modified donor cells suppress GVHD but enhance the GVL effect: a role for mitochondrial bioenergetics. <i>Blood</i> , 2014, 124, 2881-2891.	1.4	54
290	Chronic Obstructive Pulmonary Disease. <i>Deutsches A&#x0308;rztblatt International</i> , 2014, 111, 825-6.	0.9	2
291	Anti-inflammatory and immunomodulatory properties of Î±1-antitrypsin without inhibition of elastase. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, 15007-15012.	7.1	227
292	Nosocomial Infections. <i>Deutsches A&#x0308;rztblatt International</i> , 2013, 110, 625-6.	0.9	3
293	Nursing-home-acquired pneumonia in Germany: an 8-year prospective multicentre study. <i>Thorax</i> , 2012, 67, 132-138.	5.6	103
294	The lung transplant patient in the ICU. <i>Current Opinion in Critical Care</i> , 2012, 18, 472-478.	3.2	16
295	Procalcitonin to Guide Initiation and Duration of Antibiotic Treatment in Acute Respiratory Infections: An Individual Patient Data Meta-Analysis. <i>Clinical Infectious Diseases</i> , 2012, 55, 651-662.	5.8	229
296	Treatment of Sepsis-Related Organ Dysfunctionâ€”Reply. <i>JAMA - Journal of the American Medical Association</i> , 2012, 308, 1206.	7.4	1
297	Serum glucose levels for predicting death in patients admitted to hospital for community acquired pneumonia: prospective cohort study. <i>BMJ, The</i> , 2012, 344, e3397-e3397.	6.0	113
298	FMS-Like Tyrosine Kinase 3 Ligand Treatment of Mice Aggravates Acute Lung Injury in Response to <i>Streptococcus pneumoniae</i> : Role of Pneumolysin. <i>Infection and Immunity</i> , 2012, 80, 4281-4290.	2.2	19
299	Community-acquired pneumonia in younger patients is an entity on its own. <i>European Respiratory Journal</i> , 2012, 39, 1156-1161.	6.7	53
300	Biomarkers in community-acquired pneumonia. <i>Expert Review of Respiratory Medicine</i> , 2012, 6, 203-214.	2.5	34
301	Role of Mincle in Alveolar Macrophage-Dependent Innate Immunity against Mycobacterial Infections in Mice. <i>Journal of Immunology</i> , 2012, 189, 3121-3129.	0.8	75
302	TNF-related apoptosis-inducing ligand (TRAIL) exerts therapeutic efficacy for the treatment of pneumococcal pneumonia in mice. <i>Journal of Experimental Medicine</i> , 2012, 209, 1937-1952.	8.5	79
303	Procalcitonin to initiate or discontinue antibiotics in acute respiratory tract infections. , 2012, , CD007498.		169
304	Outcome of critically ill lung transplant candidates on invasive respiratory support. <i>Intensive Care Medicine</i> , 2012, 38, 968-975.	8.2	60
305	Cost Effectiveness of Budesonide/Formoterol Added to Tiotropium Bromide versus Placebo Added to Tiotropium Bromide in Patients with Chronic Obstructive Pulmonary Disease. <i>Pharmacoeconomics</i> , 2011, 29, 403-414.	3.3	20
306	Obliterative Airway Remodeling. <i>American Journal of Pathology</i> , 2011, 178, 599-608.	3.8	35

#	ARTICLE	IF	CITATIONS
307	Plexiform Lesions in Pulmonary Arterial Hypertension. American Journal of Pathology, 2011, 179, 167-179.	3.8	144
308	The discovery of α_1 -antitrypsin and its role in health and disease. Respiratory Medicine, 2011, 105, 1129-1139.	2.9	294
309	Single-centre experience with oral ribavirin in lung transplant recipients with paramyxovirus infections. Antiviral Therapy, 2011, 16, 733-740.	1.0	53
310	FOCUS 2: a randomized, double-blinded, multicentre, Phase III trial of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in community-acquired pneumonia. Journal of Antimicrobial Chemotherapy, 2011, 66, iii33-iii44.	3.0	166
311	International Pneumococcal Clones Match or Exceed the Fitness of Other Strains despite the Accumulation of Antibiotic Resistance. Antimicrobial Agents and Chemotherapy, 2011, 55, 4915-4917.	3.2	7
312	Cathepsin G and Neutrophil Elastase Play Critical and Nonredundant Roles in Lung-Protective Immunity against Streptococcus pneumoniae in Mice. Infection and Immunity, 2011, 79, 4893-4901.	2.2	100
313	Local Delivery of GM-CSF Protects Mice from Lethal Pneumococcal Pneumonia. Journal of Immunology, 2011, 187, 5346-5356.	0.8	72
314	Nosocomial methicillin-resistant staphylococcus aureus (MRSA) pneumonia: linezolid or vancomycin? - comparison of pharmacology and clinical efficacy. European Journal of Medical Research, 2010, 15, 507.	2.2	44
315	Evaluation of Biophotonic Imaging To Estimate Bacterial Burden in Mice Infected with Highly Virulent Compared to Less Virulent <i>Streptococcus pneumoniae</i> Serotypes. Antimicrobial Agents and Chemotherapy, 2010, 54, 3155-3160.	3.2	24
316	Importance of CXC Chemokine Receptor 2 in Alveolar Neutrophil and Exudate Macrophage Recruitment in Response to Pneumococcal Lung Infection. Infection and Immunity, 2010, 78, 2620-2630.	2.2	89
317	Efficacy Profiles of Daptomycin for Treatment of Invasive and Noninvasive Pulmonary Infections with <i>Streptococcus pneumoniae</i> . Antimicrobial Agents and Chemotherapy, 2010, 54, 707-717.	3.2	34
318	Antimicrobial treatment of nosocomial methicillin-resistant Staphylococcus aureus (MRSA) pneumonia: current and future options. International Journal of Antimicrobial Agents, 2010, 36, 391-400.	2.5	78
319	Assessment of inflammatory markers in patients with community-acquired pneumonia – Influence of antimicrobial pre-treatment. Clinica Chimica Acta, 2010, 411, 1929-1934.	1.1	42
320	Pro-atrial natriuretic peptide and pro-vasopressin for predicting short-term and long-term survival in community-acquired pneumonia: results from the German Competence Network CAPNETZ. Thorax, 2010, 65, 208-214.	5.6	75
321	Rethinking the concepts of community-acquired and health-care-associated pneumonia. Lancet Infectious Diseases, The, 2010, 10, 279-287.	9.1	196
322	Cardiovascular and Inflammatory Biomarkers to Predict Short- and Long-Term Survival in Community-acquired Pneumonia. American Journal of Respiratory and Critical Care Medicine, 2010, 182, 1426-1434.	5.6	195
323	Advances in the prevention, management, and treatment of community-acquired pneumonia. F1000 Medicine Reports, 2010, 2, 53.	2.9	4
324	Virus-Associated Hemophagocytic Syndrome Contributes to Fatal Outcome In Critical Ill Patients with 2009 Influenza A (H1N1) Infection.. Blood, 2010, 116, 3795-3795.	1.4	0

#	ARTICLE	IF	CITATIONS
325	C-terminal proavopressin (copeptin) in patients with community-acquired pneumonia–influence of antibiotic pre-treatment: results from the German competence network CAPNETZ. <i>Journal of Antimicrobial Chemotherapy</i> , 2009, 64, 159-162.	3.0	31
326	Important Role for CC Chemokine Ligand 2-Dependent Lung Mononuclear Phagocyte Recruitment to Inhibit Sepsis in Mice Infected with <i>Streptococcus pneumoniae</i> . <i>Journal of Immunology</i> , 2009, 182, 4931-4937.	0.8	65
327	10 years™ experience with the pneumococcal quinolone moxifloxacin. <i>Expert Review of Anti-Infective Therapy</i> , 2009, 7, 645-668.	4.4	21
328	Global and Local Epidemiology of Community-Acquired Pneumonia: The Experience of the CAPNETZ Network. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2009, 30, 127-135.	2.1	105
329	Efficacy and Tolerability of Budesonide/Formoterol Added to Tiotropium in Patients with Chronic Obstructive Pulmonary Disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2009, 180, 741-750.	5.6	339
330	<i>Mycoplasma pneumoniae</i> pneumonia revisited within the German Competence Network for Community-acquired pneumonia (CAPNETZ). <i>BMC Infectious Diseases</i> , 2009, 9, 62.	2.9	66
331	Tigecycline possibly underdosed for the treatment of pneumonia: a pharmacokinetic viewpoint. <i>International Journal of Antimicrobial Agents</i> , 2009, 34, 101-102.	2.5	87
332	Inflammatory parameters predict etiologic patterns but do not allow for individual prediction of etiology in patients with CAP – Results from the German competence network CAPNETZ. <i>Respiratory Research</i> , 2009, 10, 65.	3.6	101
333	Inhaled corticosteroids in COPD and the risk of pneumonia. <i>Lancet</i> , The, 2009, 374, 668-670.	13.7	25
334	Community-Acquired Respiratory Viral Infections in Lung Transplant Recipients: A Single Season Cohort Study. <i>Transplantation</i> , 2009, 87, 1530-1537.	1.0	141
335	Overexpression of cathepsin K in mice decreases collagen deposition and lung resistance in response to bleomycin-induced pulmonary fibrosis. <i>Respiratory Research</i> , 2008, 9, 54.	3.6	50
336	Community-Acquired <i>Legionella</i> Pneumonia: New Insights from the German Competence Network for Community Acquired Pneumonia. <i>Clinical Infectious Diseases</i> , 2008, 46, 1356-1364.	5.8	188
337	Importance of Phosphoinositide 3-Kinase \hat{I}^3 in the Host Defense against Pneumococcal Infection. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2007, 175, 958-966.	5.6	73
338	Mediator responses of alveolar macrophages and kinetics of mononuclear phagocyte subset recruitment during acute primary and secondary mycobacterial infections in the lungs of mice. <i>Cellular Microbiology</i> , 2007, 9, 738-752.	2.1	44
339	Pro-atrial natriuretic peptide and pro-vasopressin to predict severity and prognosis in community-acquired pneumonia. <i>Intensive Care Medicine</i> , 2007, 33, 2069-2078.	8.2	87
340	Asthma and COPD. <i>Experimental and Toxicologic Pathology</i> , 2006, 57, 35-40.	2.1	44
341	Fibroblasts of Recipient Origin Contribute to Bronchiolitis Obliterans in Human Lung Transplants. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2006, 173, 1276-1282.	5.6	76
342	Reply to Solnick and to Leenders. <i>Clinical Infectious Diseases</i> , 2006, 43, 110-111.	5.8	1

#	ARTICLE	IF	CITATIONS
343	Resident Alveolar Macrophages Are Replaced by Recruited Monocytes in Response to Endotoxin-Induced Lung Inflammation. American Journal of Respiratory Cell and Molecular Biology, 2006, 35, 227-235.	2.9	161
344	Cost Analyses of Community-Acquired Pneumonia From the Hospital Perspective. Chest, 2005, 128, 2238-2246.	0.8	68
345	Reduktion von Air-Trapping durch optimale Bronchodilatation. Medizinische Klinik - Intensivmedizin Und Notfallmedizin, 2005, 100, 9-11.	1.1	0
346	The Inflammatory versus Constitutive Trafficking of Mononuclear Phagocytes into the Alveolar Space of Mice Is Associated with Drastic Changes in Their Gene Expression Profiles. Journal of Immunology, 2005, 175, 1884-1893.	0.8	79
347	Treatment with Sequential Intravenous or Oral Moxifloxacin Was Associated with Faster Clinical Improvement than Was Standard Therapy for Hospitalized Patients with Community-Acquired Pneumonia Who Received Initial Parenteral Therapy. Clinical Infectious Diseases, 2005, 41, 1697-1705.	5.8	92
348	A case of influenza vaccination induced Guillain Barré syndrome with normal cerebrospinal fluid protein and improvement on treatment with corticosteroids. Scandinavian Journal of Infectious Diseases, 2005, 37, 621-623.	1.5	2
349	Role of Fluoroquinolones in the Treatment of Community-Acquired Pneumonia. , 0, , 193-212.		0
350	Essenzielle Praxisfragen: Herzessache COPD. Deutsches Ärztblatt International, 0, , .	0.9	0
351	Benefit of monoclonal antibodies in early treatment of COVID-19 after lung transplantation â€œ a retrospective analysis in two centers. European Respiratory Journal, 0, , 2200124.	6.7	3